Refine
Year of publication
Document Type
- Article (83) (remove)
Has Fulltext
- yes (83)
Is part of the Bibliography
- no (83)
Keywords
- ADHD (17)
- Depression (8)
- Bipolar disorder (7)
- Genetics (6)
- bipolar disorder (5)
- Human behaviour (4)
- Psychiatric disorders (4)
- Dopamine (3)
- Neuroscience (3)
- Physical activity (3)
- Suicide (3)
- Treatment (3)
- fMRI (3)
- Attention-deficit/hyperactivity disorder (2)
- Biomarker (2)
- Brain (2)
- Clinical genetics (2)
- Comorbidity (2)
- Diagnostic markers (2)
- Emotion regulation (2)
- Exercise (2)
- Inflammation (2)
- L-DOPA (2)
- Major depressive disorder (2)
- PARK2 (2)
- Predominant polarity (2)
- Primary care (2)
- attention (2)
- biomarker (2)
- continuous performance test (2)
- depression (2)
- hyperactivity (2)
- impulsivity (2)
- machine learning (2)
- polygenic risk score (2)
- schizophrenia (2)
- 14-3-3 gene family (1)
- A2BP1 (1)
- ADHD differential diagnosis (1)
- AKI (1)
- Accidents (1)
- Adjuvant procedure (1)
- Adjuvantes Verfahren (1)
- Adult-onset ADHD (1)
- Affect (1)
- Affective disorders (1)
- Agoraphobia (1)
- Ambulatory Assessment (1)
- Amino acids (1)
- Amisulpride (1)
- Amphetamine (1)
- Amygdala (1)
- Animal models (1)
- Antidepressant (1)
- Anxiolytic pharmacological therapy (1)
- Atomoxetine (1)
- Attention (1)
- Attention Deficit Hyperactivity Disorder (ADHD) (1)
- Attention deficit (1)
- Attention-deficit / hyperactivity disorder (1)
- Attentional bias (1)
- Batten disease (1)
- Behavioral tests (1)
- Big Five (1)
- Brain DNA methylation (1)
- Bright light therapy (1)
- Brms (1)
- Brodalumab (1)
- CAPON (1)
- CDH13 (1)
- CNVs (1)
- COMT (1)
- COVID-19 (1)
- Cardiac surgery (1)
- Circadian (1)
- Cln3 (1)
- Co-morbidity (1)
- Cognitive (1)
- Cognitive dysfunction (1)
- Cognitive enhancers of exposure therapy (1)
- Cognitive impairment (1)
- Comorbidities (1)
- Completed suicide (1)
- Consensus (1)
- Copy number (1)
- Course (1)
- DTI (1)
- DYT1 (1)
- Developmental programming (1)
- Developmental trajectory (1)
- Diagnosis (1)
- Diagnostic medicine (1)
- Diagnostic test (1)
- Dietary intake (1)
- Differential diagnosis (1)
- Dot-probe task (1)
- EBM (1)
- Early (prenatal and postnatal) life experiences (1)
- Ecological Momentary Assessment (EMA) (1)
- Ecological momentary assessment (1)
- Energy (1)
- Environmental enrichment (1)
- Epigenetics (1)
- Euthymic phase (1)
- Evidence-based (1)
- Evidence-based drug discovery (1)
- Evidenzbasierung (1)
- Explicit (1)
- Fruit fly (1)
- GHQ-28 (1)
- GWAS (1)
- Gaba (1)
- Gene (1)
- Genetic syndromes (1)
- Guidelines (1)
- Healthy Living Index (HLI) (1)
- Hippocampus (1)
- Hyperactivity (1)
- IL-17 (1)
- Imaging genetics (1)
- Immunity (1)
- Immunogenetics (1)
- Immunology (1)
- Implicit (1)
- Injuries (1)
- Intervention (1)
- KDIGO (1)
- Konsens (1)
- LFP (1)
- Lafora disease (1)
- Langzeiteffekt (1)
- Learning and memory (1)
- Leitlinien (1)
- Lithium (1)
- Long-term effect (1)
- Longitudinal (1)
- MDD (1)
- MVPA (1)
- Maintenance treatment (1)
- Mania (1)
- Maternal separation (1)
- Mechanism of action (1)
- Memory (1)
- Mental disorder (1)
- Mental health and psychiatry (1)
- Mental health disorders (1)
- Metabolic diseases (1)
- Methylphenidate (1)
- Mitochondrial dysfunction (1)
- Molecular neuroscience (1)
- Monetary incentive delay (1)
- Mood (1)
- Mouse (1)
- Multilevel two-part modelling (1)
- Multiplex immunoassay (1)
- NOS-I (1)
- NOS1AP (1)
- NPSR1 (1)
- Nesplora Aquarium (1)
- Neurodevelopmental disorder (1)
- Neuromodulatorisches Netzwerk (1)
- Neuromodulatory network (1)
- Neurostimulation (1)
- Norepinephrine (1)
- Obesity (1)
- Outcome (1)
- Pandemic (1)
- Panic disorder (1)
- Patients (1)
- Personalized medicine (1)
- Phenylketonuria (PKU) (1)
- Physical fitness (1)
- Physical self-perception (1)
- Physicians (1)
- Polarity index (1)
- Polygenic risk score (1)
- Postvention (1)
- Prediction (1)
- Predictive markers (1)
- Psychedelics (1)
- Psychiatric traits (1)
- Psychiatry (1)
- Qb-Test (1)
- QbTest® (1)
- Quality of life (1)
- R (1)
- RBFOX1 (1)
- RDoC (1)
- RNAi (1)
- Randomized controlled trial (1)
- Research article (1)
- Reward (1)
- Rodents (1)
- SARS-CoV2 (1)
- SUD (1)
- Schizophrenia (1)
- Scientific community (1)
- Seasonal variation (1)
- Self-efficacy (1)
- Self-esteem (1)
- Semicontinuous (1)
- Solar insolation (1)
- Stimulant (1)
- Stress resilience (1)
- Stress vulnerability/resilience genes (1)
- Striatum (1)
- Suicidal behavior (1)
- Suicidal thoughts (1)
- Suicidality (1)
- Suicide attempt (1)
- Suizidalität (1)
- Sunlight (1)
- Synaptic dysfunction (1)
- TBSS (1)
- TOR1A (1)
- Trajectories (1)
- Two-hit hypothesis (1)
- Tyrosinemia (1)
- UPPS (1)
- Westphal-Paradigm (1)
- Wirkmechanismus (1)
- Working memory capacity (1)
- YWHAE (1)
- YWHAZ (1)
- Yoga (1)
- Zebrafish (1)
- accidents (1)
- adaptation (1)
- adeno-associated virus (1)
- adult attention deficit/hyperactivity disorder (adult ADHD) (1)
- adversity (1)
- affective disorder (1)
- affective disorders (1)
- aggressiveness (1)
- aging (1)
- agreeableness (1)
- alcohol use disorder (1)
- allostasis (1)
- amisulpride (1)
- associative memory (1)
- attention deficit hyperactivity disorder (1)
- attention-deficit/hyperactivity disorder (1)
- autism (1)
- bipolar disorders (1)
- blood (1)
- body mass index (1)
- ceramides (1)
- children (1)
- cognition (1)
- common variant (1)
- common variants (1)
- comorbidity (1)
- coping (1)
- cross-sectional study (1)
- data science (1)
- dementia (1)
- development (1)
- diabetes mellitus (1)
- disease modelling (1)
- dopamine (1)
- dynamic system (1)
- early recognition (1)
- endocannabinoids (1)
- epigenetics (1)
- epilepsy (1)
- euthymic (1)
- ex-Gaussian analysis (1)
- executive functions (1)
- expression studies (1)
- extraversion (1)
- face-name association task (1)
- fear conditioning (1)
- fear generalization (1)
- functional connectivity (1)
- gender (1)
- genetic phenotypes (1)
- genetic variants (1)
- genetics (1)
- gene×environment interactions (1)
- glucose metabolism (1)
- graph theory (1)
- hiPSC (1)
- homeostasis (1)
- inflammation (1)
- insula (1)
- insulin resistance (1)
- juvenile myoclonic epilepsy (1)
- lifestyle (1)
- lipids (1)
- machine learning (ML) (1)
- major depression (1)
- major depression (MD) (1)
- major depressive disorder (1)
- major depressive disorder (MDD) (1)
- maturation (1)
- mental health (1)
- metabolic syndrome (1)
- mitochondria (1)
- morphometry (1)
- nNOS (1)
- naturalistic sample (1)
- neurodevelopment (1)
- neurodevelopmental disorders (1)
- neuropsychology (1)
- neuroticism (1)
- nitric oxide (1)
- obesity (1)
- pharmaco-fMRI (1)
- pharmacogenetics (1)
- pharmacoresistance (1)
- prediabetes (1)
- progressive myoclonus epilepsy (1)
- proteome (1)
- psychiatric disorders (1)
- psychosocial stress (1)
- rare mendelian disorders (1)
- rare variant (1)
- rare variants (1)
- resting-state fMRI (1)
- resting‐state (1)
- risk genes (1)
- schizophrenia spectrum (1)
- skin conductance (1)
- stress (1)
- substance abuse disorder (1)
- tandem mass spectrometry (1)
- transcriptomics (1)
- ventral tegmental area (1)
- venturesomeness (1)
- viral gene transfer (1)
- white-matter (1)
- working memory (1)
Institute
- Medizin (83) (remove)
Predominant polarity in bipolar disorder and validation of the polarity index in a German sample
(2014)
Background: A large number of patients with bipolar disorder (BD) can be characterized by predominant polarity (PP), which has important implications for relapse prevention. Recently, Popovic et al. (EUR NEUROPSYCHOPHARM 22(5): 339¿346, 2012) proposed the Polarity Index (PI) as a helpful tool in the maintenance treatment of BD. As a numeric expression, it reflects the efficacy of drugs used in treatment of BD. In the present retrospective study, we aimed to validate this Index in a large and well characterized German bipolar sample.
Methods: We investigated 336 bipolar patients (BP) according to their PP and calculated the PI for each patient in order to prove if maintenance treatment differs according to their PP. Furthermore, we analysed whether PP is associated with demographic and clinical characteristics of BP.
Results: In our sample, 63.9% of patients fulfilled criteria of PP: 169 patients were classified as depressive predominant polarity (DPP), 46 patients as manic predominant polarity (MPP). The two groups differed significantly in their drug regime: Patients with DPP were more often medicated with lamotrigine and antidepressants, patients with MPP were more often treated with lithium, valproate, carbamazepine and first generation antipsychotics. However, patients with DPP and MPP did not differ significantly with respect to the PI, although they received evidence-based and guideline-driven treatment.
Conclusion: The reason for this negative finding might well be that for several drugs, which were used frequently, no PI value is available. Nevertheless we suggest PP as an important concept in the planning of BD maintenance treatment.
The precise understanding of the dopaminergic (DA) system and its pharmacological modifications is crucial for diagnosis and treatment of neuropsychiatric disorders, as well as for understanding basic processes, such as motivation and reward. We probed the functional connectivity (FC) of subcortical nuclei related to the DA system according to seed regions defined according to an atlas of subcortical nuclei. We conducted a large pharmaco-fMRI study using a double-blind, placebo-controlled design, where we examined the effect of l -DOPA, a dopamine precursor, and amisulpride, a D2/D3-receptor antagonist on resting-state FC in 45 healthy young adults using a cross-over design. We examined the FC of subcortical nuclei with connection to the reward system and their reaction to opposing pharmacological probing. Amisulpride increased FC from the putamen to the precuneus and from ventral striatum to precentral gyrus. l -DOPA increased FC from the ventral tegmental area (VTA) to the insula/operculum and between ventral striatum and ventrolateral prefrontal cortex and it disrupted ventral striatal and dorsal caudate FC with the medial prefrontal cortex. In an exploratory analysis, we demonstrated that higher self-rated impulsivity goes together with a significant increase in VTA-mid-cingulate gyrus FC during l -DOPA-challenge. Therefore, our DA challenge modulated distinct large-scale subcortical connectivity networks. A dopamine-boost can increase midbrain DA nuclei connectivity to the cortex. The involvement of the VTA-cingulum connectivity in dependence of impulsivity has implications for diagnosis and therapy in disorders like ADHD.
TOR1A is the most common inherited form of dystonia with still unclear pathophysiology and reduced penetrance of 30–40%. ∆ETorA rats mimic the TOR1A disease by expression of the human TOR1A mutation without presenting a dystonic phenotype. We aimed to induce dystonia-like symptoms in male ∆ETorA rats by peripheral nerve injury and to identify central mechanism of dystonia development. Dystonia-like movements (DLM) were assessed using the tail suspension test and implementing a pipeline of deep learning applications. Neuron numbers of striatal parvalbumin+, nNOS+, calretinin+, ChAT+ interneurons and Nissl+ cells were estimated by unbiased stereology. Striatal dopaminergic metabolism was analyzed via in vivo microdialysis, qPCR and western blot. Local field potentials (LFP) were recorded from the central motor network. Deep brain stimulation (DBS) of the entopeduncular nucleus (EP) was performed. Nerve-injured ∆ETorA rats developed long-lasting DLM over 12 weeks. No changes in striatal structure were observed. Dystonic-like ∆ETorA rats presented a higher striatal dopaminergic turnover and stimulus-induced elevation of dopamine efflux compared to the control groups. Higher LFP theta power in the EP of dystonic-like ∆ETorA compared to wt rats was recorded. Chronic EP-DBS over 3 weeks led to improvement of DLM. Our data emphasizes the role of environmental factors in TOR1A symptomatogenesis. LFP analyses indicate that the pathologically enhanced theta power is a physiomarker of DLM. This TOR1A model replicates key features of the human TOR1A pathology on multiple biological levels and is therefore suited for further analysis of dystonia pathomechanism.
Rationale: Dysregulation of dopaminergic neurotransmission, specifically altered reward processing assessed via the reward anticipation in the MID task, plays a central role in the etiopathogenesis of neuropsychiatric disorders. Objectives: We hypothesized to find a difference in the activity level of the reward system (measured by the proxy reward anticipation) under drug administration versus placebo, in that amisulpride reduces, and L-DOPA enhances, its activity. Methods: We studied the influence of dopamine agonist L-DOPA and the antagonist amisulpride on the reward system using functional magnetic resonance imaging (fMRI) during a monetary incentive delay (MID) task in n = 45 healthy volunteers in a randomized, blinded, cross-over study. Results: The MID paradigm elicits strong activation in reward-dependent structures (such as ventral striatum, putamen, caudate, anterior insula) during reward anticipation. The placebo effect demonstrated the expected significant blood oxygen level–dependent activity in reward-dependent brain regions. Neither amisulpride nor L-DOPA led to significant changes in comparison with the placebo condition. This was true for whole-brain analysis as well as analysis of a pre-defined nucleus accumbens region-of-interest mask. Conclusion: The present results cast doubt on the sensitivity of reward anticipation contrast in the MID task for assessing dopamine-specific changes in healthy volunteers by pharmaco-fMRI. While our task was not well-suited for detailed analysis of the outcome phase, we provide reasonable arguments that the lack of effect in the anticipation phase is not due to an inefficient task but points to unexpected behavior of the reward system during pharmacological challenge. Group differences of reward anticipation should therefore not be seen as simple representatives of dopaminergic states.
New innovative neuropsychological tests in attention deficit hyperactivity disorder ADHD have been proposed as objective measures for diagnosis and therapy. The current study aims to investigate two different commercial continuous performance tests (CPT) in a head-to-head comparison regarding their comparability and their link with clinical parameters. The CPTs were evaluated in a clinical sample of 29 adult patients presenting in an ADHD outpatient clinic. Correlational analyses were performed between neuropsychological data, clinical rating scales, and a personality-based measure. Though inattention was found to positively correlate between the two tests (r = 0.49, p = 0.01), no association with clinical measures and inattention was found for both tests. While hyperactivity did not correlate between both tests, current ADHD symptoms were positively associated with Nesplora Aquarium’s motor activity (r = 0.52 to 0.61, p < 0.05) and the Qb-Test’s hyperactivity (r = 0.52 to 0.71, p < 0.05). Conclusively, the overall comparability of the tests was limited and correlation with clinical parameters was low. While our study shows some interesting correlation between clinical symptoms and sub-scales of these tests, usage in clinical practice is not recommended.
The quantified behavioral test - a confirmatory test in the diagnostic process of adult ADHD?
(2020)
The differential diagnosis of attention deficit hyperactivity disorder (ADHD) in adulthood is complicated by comorbid disorders, but also by the overlapping of main symptoms such as inattentiveness, impulsivity, and hyperactivity with other disorders. Neuropsychological tests like continuous performance tests (CPT) try to solve this dilemma by objectively measurable parameters. We investigated in a cohort of n=114 patients presenting to an ADHD outpatient clinic how well a commercially available CPT test (QbTest®) can differentiate between patients with ADHD (n=94) and patients with a disconfirmed ADHD diagnosis (n=20). Both groups showed numerous comorbidities, predominantly depression (27.2% in the ADHD group vs. 45% in the non-ADHD group) and substance-use disorders (18.1% vs. 10%, respectively). Patients with ADHD showed significant higher activity (2.07 ± 1.23) than patients without ADHD (1.34 ± 1.27, dF=112; p=0.019), whereas for the other core parameters, inattention and impulsivity no differences could be found. Reaction time variability has been discussed as a typical marker for inattention in ADHD. Therefore, we investigated how well ex-Gaussian analysis of response time can differentiate between ADHD and other patients, showing, that it does not help to identify patients with ADHD. Even though patients with ADHD showed significantly higher activity, this parameter differed only poorly between patients (accuracy AUC 65% of an ROC-Curve). We conclude that CPTs do not help to identify patients with ADHD in a specialized outpatient clinic. The usability of this test for differentiating between ADHD and other psychiatric disorders is poor and a sophisticated analysis of reaction time did not decisively increase the test accuracy.
Attention-deficit/hyperactivity disorder (ADHD) is a common and highly heritable neurodevelopmental disorder. In recent years, genetic studies have revealed several risk gene variants associated with ADHD; however, these variants could only be partly replicated and are responsible for only a fraction of the whole heritability of ADHD estimated from family and twin studies. One factor that could potentially explain the ‘missing heritability’ of ADHD is that childhood and adult or persistent ADHD could be genetically distinct subtypes, which therefore need to be analyzed separately. Another approach to identify this missing heritability could be combining the investigation of both common and rare gene risk variants as well as polygenic risk scores. Finally, environmental factors are also thought to play an important role in the etiology of ADHD, acting either independently of the genetic background or more likely in gene–environment interactions. Environmental factors might additionally convey their influence by epigenetic mechanisms, which are relatively underexplored in ADHD. The aforementioned mechanisms might also influence the response of patients with ADHD to stimulant and other ADHD medication. We conducted a selective review with a focus on risk genes of childhood and adult ADHD, gene–environment interactions, and pharmacogenetics studies on medication response in childhood and adult ADHD.
Background: Recent research has shown an increased risk of accidents and injuries in ADHD patients, which could potentially be reduced by stimulant treatment. Therefore, the first aim of our study was to evaluate the prevalence of adult ADHD in a trauma surgery population. The second aim was to investigate accident mechanisms and circumstances which could be specific to ADHD patients, in comparison to the general population.
Methods: We screened 905 accident victims for ADHD using the ASRS 18-item self-report questionnaire. The basic demographic data and circumstances of the accidents were also assessed.
Results: Prevalence of adult ADHD was found to be 6.18% in our trauma surgery patient sample. ADHD accident victims reported significantly higher rates of distraction, stress and overconfidence in comparison to non-ADHD accident victims. Overconfidence and being in thoughts as causal mechanisms for the accidents remained significantly higher in ADHD patients after correction for multiple comparison. ADHD patients additionally reported a history of multiple accidents.
Conclusion: The majority of ADHD patients in our sample had not previously been diagnosed and were therefore not receiving treatment. The results subsequently suggest that general ADHD screening in trauma surgery patients may be useful in preventing further accidents in ADHD patients. Furthermore, psychoeducation regarding specific causal accident mechanisms could be implemented in ADHD therapy to decrease accident incidence rate.
The major depressive disorder is one of the most common mental illnesses worldwide. Current treatment standards recommend a combined therapy with medication and psychotherapy. As an additive component and to further improvements in treatment, physical activity such as yoga may be integrated into conventional treatment. This study investigates the impact of a 3-month body-oriented yoga in patients with major depressive disorder (MDD). In total, n = 83 patients were included. An intervention group received a vigorous Ashtanga-Yoga three times a week. The waiting-list control group obtained a treatment as usual (TAU). As a primary outcome depression scores (Beck Depression Inventory-II (BDI-II), Montgomery Asberg Depression Rating Scale (MADRS)) were tested at three time points. Secondary outcome was the positive and negative affect [Positive and Negative Affect Scale (PANAS)] and remission rates. To analyze the data, multilevel models and effect sizes were conducted. The results showed an improvement in BDI-II scores for both groups over time [γ = − 3.46, t(165) = − 7.99, p < 0.001] but not between groups [γ = 0.98, t(164) = 1.12, p = 0.263]. An interaction effect (time x group) occurred for MADRS [γ = 2.10, t(164) = 2.10, p < 0.038]. Positive affects improved over time for both groups [γ = 1.65, t(165) = 4.03, p < 0.001]. Negative affects decreased for all over time [γ = − 1.00, t(165) = − 2.51, p = 0.013]. There were no significant group differences in PANAS. Post hoc tests revealed a greater symptom reduction within the first 6 weeks for all measurements. The effect sizes for depression scores showed a positive trend. Remission rates indicated a significant improvement in the yoga group (BDI-II: 46.81%, MADRS: 17.02%) compared to the control group (BDI: 33.33%, MADRS: 8.33%). The findings suggest that there is a trendsetting additive effect of Ashtanga-Yoga after 3 months on psychopathology and mood with a greater improvement at the beginning of the intervention. Further research in this field can help to achieve more differentiated results.
Physical inactivity is discussed as one of the most detrimental influences for lifestyle-related medical complications such as obesity, heart disease, hypertension, diabetes and premature mortality in in- and outpatients with major depressive disorder (MDD). In contrast, intervention studies indicate that moderate-to-vigorous-intensity physical activity (MVPA) might reduce complications and depression symptoms itself. Self-reported data on depression [Beck-Depression-Inventory-II (BDI-II)], general habitual well-being (FAHW), self-esteem and physical self-perception (FAHW, MSWS) were administrated in a cross-sectional study with 76 in- and outpatients with MDD. MVPA was documented using ActiGraph wGT3X + ® accelerometers and fitness was measured using cardiopulmonary exercise testing (CPET). Subgroups were built according to activity level (low PA defined as MVPA < 30 min/day, moderate PA defined as MVPA 30–45 min/day, high PA defined as MVPA > 45 min/day). Statistical analysis was performed using a Mann–Whitney U and Kruskal–Wallis test, Spearman correlation and mediation analysis. BDI-II scores and MVPA values of in- and outpatients were comparable, but fitness differed between the two groups. Analysis of the outpatient group showed a negative correlation between BDI-II and MVPA. No association of inpatient MVPA and psychopathology was found. General habitual well-being and self-esteem mediated the relationship between outpatient MVPA and BDI-II. The level of depression determined by the BDI-II score was significantly higher in the outpatient low- and moderate PA subgroups compared to outpatients with high PA. Fitness showed no association to depression symptoms or well-being. To ameliorate depressive symptoms of MDD outpatients, intervention strategies should promote habitual MVPA and exercise exceeding the duration recommended for general health (≥ 30 min/day). Further studies need to investigate sufficient MVPA strategies to impact MDD symptoms in inpatient settings. Exercise effects seem to be driven by changes of well-being rather than increased physical fitness.